<DOC>
	<DOCNO>NCT01894308</DOCNO>
	<brief_summary>This study continuation previous study do healthy volunteer prove efficacy deliver Testosterone , male hormone , rapidly across intact skin series dos low high men low-to-no natural testosterone production measure response varying dos . The result study inform study longer length , start dos . The study conduct London , U.K. Advanced Therapies Centre , The London Clinic .</brief_summary>
	<brief_title>A Dose Ranging Study Examine Testagen® TDS-Testosterone 5 %</brief_title>
	<detailed_description>48 Patients enrol follow 2 independent verify blood test diagnosis Hypogonadism . 4 cohort 12 subject , receive dos trail material , titrate mean number spray apply . Doses range 10 70 mg Testosterone .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Hypogonadal Male subject morning testosterone level ≤300 ng/dL ( 10.4 ng/L ) . 2 . 18 75 year age , inclusive . 3 . The subject willing able read , understand Subject Information Sheet provide write informed consent . 4 . The subject body mass index ( BMI ) within 1830 kg/m2 . 5 . The subject otherwise good health determine medical history physical examination . 6 . The subject nonsmoker . 7 . The subject must agree comply placement indwell catheter two separate occasion draw blood sample pharmacokinetic assessment . 8 . The subject willing able comply test requirement define protocol . 9 . The subject willing able return study site visit . 1 . The subject relevant deviation normal physical examination , electrocardiogram ( ECG ) , clinical laboratory test , evaluate investigator , particularly elevate PSA read &gt; 4.0 ng/ml ALT AST great 2 time upper limit normal , clinically significant anemia ( hematocrit &lt; 35 % ) renal dysfunction ( creatinine &gt; 2mg/dL ) , active deep vein thrombosis , thromboembolic disorder history condition . 2 . The subject clinically significant illness within 30 day precede entry study . 3 . The subject history significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , metabolic disease . 4 . The subject know allergy history hypersensitivity Testosterone similar compound . 5 . The subject use prescription medication within 14 day overthecounter ( OTC ) medication alcohol within 48 hour dose intend use prescription OTC medication study may interfere evaluation study medication . 6 . The subject donate lost significant volume blood ( &gt; 450 mL ) within four ( 4 ) week study , haemoglobin concentration haematocrit return within 5 % normal . 7 . The subject Hematocrit level &gt; 51 % 8 . The subject history substance abuse current positive urine drug screen urine alcohol test . 9 . Alcohol consumption great community norm ( i.e . 21 standard drink per week male ) . 10 . Subjects receive investigational drug use investigational device 30 day prior study entry . 11 . Subjects American Urological Association System Index Prostatism score great 7 12 . Subjects history prostate breast carcinoma . 13 . Subjects prostatic mass screen physical examination . 14 . Subjects history significant skin disease . 15 . Subjects history sleep apnea . 16 . Subject partner history breast cancer . 17 . Subject partner child bear potential willing use adequate contraception duration trial . 18 . Subject whose partner pregnant .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Male Hormone Replacement</keyword>
	<keyword>Multiple Dose</keyword>
	<keyword>Single Period</keyword>
	<keyword>Phase II</keyword>
	<keyword>Dose Ranging</keyword>
	<keyword>Adult Male Subjects</keyword>
	<keyword>Testosterone Replacement</keyword>
</DOC>